Aspen
Aspen API is a pharmaceutical CDMO and API manufacturer operating as a business unit of Aspen Pharmacare, producing 60+ complex APIs including HPAPIs, peptides, narcotics, and botanicals across facilities in the Netherlands, South Africa, and USA for multinational, generic, and biotech pharmaceutical customers.
- Company typePrivate
- Founded1923
- HeadquartersDurban, South Africa
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Aspen does
Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and commercial-scale production of complex Active Pharmaceutical Ingredients (APIs). The company operates as a business unit of Aspen Pharmacare Holdings Limited, a JSE-listed pharmaceutical conglomerate, with origins dating back to 1923 in the Netherlands (initially extracting animal pancreases for insulin) and a parallel South African lineage via Fine Chemicals Corporation (founded 1962, acquired by Aspen in 2004). Its manufacturing footprint spans four production sites — Oss (Netherlands, two facilities), Boxtel (Netherlands), Cape Town (South Africa via FCC), and Sioux City (USA) — supported by regional sales offices in Des Plaines (USA) and Tokyo (Japan).
The core product portfolio exceeds 60 established APIs organized into five technical sub-categories: High Potency & Oncology APIs manufactured under OEB 4/5 containment with OEL levels as low as 0.01 µg/m³; Peptides produced via proprietary GREEN CONTINUOUS LPPS alongside classical LPPS and SPPS methods; Narcotic & Analgesic APIs (UN INCB recognized) produced at FCC; Botanical Extraction APIs; and biochemical products such as Chorionic Gonadotrophin. The technology platform encompasses complex chemistries (ethynylation, Grignard, catalytic hydrogenation, bromination, hydride reductions) and advanced analytical capabilities (HRMS, LC-MS/MS, 500MHz NMR) running across 100+ stainless steel and glass-lined reactor vessels ranging from 100L to 10,000L.
Revenue is generated through two principal streams: project-based and long-term Contract Development and Manufacturing agreements (CDMO/CMO services spanning route selection, process development, scale-up, analytical validation, and commercial manufacturing) and commercial supply of established APIs to global pharmaceutical customers. The company sells exclusively on a B2B basis into three horizontally-segmented customer groups — multinational originator pharmaceutical companies, generic drug manufacturers, and innovative biotech startups — via a dedicated direct enterprise sales team supplemented by local distributors and regional offices. Pricing is contractually negotiated and not publicly disclosed, with revenue mechanics tied to project complexity, volume, and regulatory requirements.
Aspen firmographics
Firmographics- Name
- Aspen
- Legal name
- Aspen Oss B.V.
- Website
- https://aspenapi.com
- Company type
- Private
- Founded year
- 1923
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Aspen API is a pharmaceutical CDMO and API manufacturer operating as a business unit of Aspen Pharmacare, producing 60+ complex APIs including HPAPIs, peptides, narcotics, and botanicals across facilities in the Netherlands, South Africa, and USA for multinational, generic, and biotech pharmaceutical customers.
- Ownership category
- akta.pro rank
Aspen industry classification
Industry- Product category
- Pharmaceutical API Manufacturing
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Aspen is headquartered
LocationHeadquarters
- HQ city
- Durban
- HQ country
- South Africa
- HQ region
- Africa
Offices7 records
Markets served
Aspen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Contract Development and Manufacturing (CDMO/CMO): Full-service API development and manufacturing for pharmaceutical companies. Services include process development, scale-up, analytical development, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts and long-term manufacturing agreements with multinationals, generic manufacturers, and biotech companies.
- Established API Product Sales: Sale of more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Revenue from product supply contracts to pharmaceutical customers globally.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Aspen product offering
Product offeringCore offering
Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredient (API) development and manufacturing. The company provides end-to-end services from process development and analytical development through commercial manufacturing, supported by more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Operations span four manufacturing facilities in the Netherlands, South Africa, and the United States, with regulatory approvals from US FDA, EMA, PMDA, EDQM, and other major health authorities.
Product overview
Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredients (APIs). The company operates as a single unified offering combining CDMO Solutions with an Established API Portfolio of more than 60 high-quality APIs. The core products span High Potency & Oncology APIs (HPAPIs with OEB 4/5 classifications), Peptides (manufactured via LPPS, SPPS, and proprietary GREEN CONTINUOUS LPPS technology), Narcotics & Analgesic APIs, Botanical Extraction APIs, and Chorionic Gonadotrophin. Supporting services include Analytical Development, Regulatory Support, and a broad Technology Platform enabling complex chemical reactions. The company operates facilities in the Netherlands (Oss, Boxtel), South Africa (Cape Town), and USA (Sioux City, Iowa), serving multinationals, generic manufacturers, and innovative biotech companies.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Successfully passed multiple FDA inspections with no critical findings or Form 483 issued (7 successive US FDA inspections, last audit July 2018)
- +2 more outcomes
Companies that use Aspen
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Aspen technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aspen partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Fine Chemicals Corporation (FCC)coreFCC is a wholly owned subsidiary of Aspen API located in Cape Town, South Africa. Specializes in narcotics, botanical extraction, and oncology APIs. Manufacturing approval from US FDA, PMDA, TGA, SAHPRA, EDQM/ANSM.
- Health Valley NetherlandsminorCollaboration with the biggest Dutch Life Sciences & Health innovation network for staying informed about latest developments and innovation in the sector.
- Educational Institutes (MSc and BSc)minorClose contacts with educational institutes for innovation, knowledge sharing, and staying current with latest scientific developments.
- APIC (Active Pharmaceutical Ingredients Committee)coreActive and valued member directly involved in discussions within EMA, FDA, EDQM and ICH. Plays key role in expert panels and participates in USP and EP expert groups.
- Wageningen Food and Biobased ResearchminorCollaboration on sustainable API production research and development projects.
- Studievereniging Jan Pieter Minckelers (TU Eindhoven)minorInspiring collaboration with study association for Chemical Engineering and Chemistry students. Aspen sponsors the association and shares knowledge through activities.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Aspen competitors and assessment
Company assessmentDirect peers
- Axplora (formerly Novasep): European CDMO specializing in complex APIs including HPAPIs, peptides, and highly potent compounds. Direct comparable to Aspen API's peptide manufacturing capabilities and HPAPI containment at OEB 4/5 levels with overlapping technology stacks in continuous flow and preparative chromatography.
- Piramal Pharma Solutions: India-headquartered CDMO with strong HPAPI and ADC payload manufacturing capabilities. Directly competes with Aspen API for high-potency oncology API contracts, with comparable OEB 4/5 containment infrastructure and global regulatory expertise (FDA, EMA, PMDA).
- Lonza: Swiss-headquartered global CDMO and the world's largest contract API manufacturer with deep HPAPI and peptide capabilities. Directly comparable to Aspen API across small-molecule APIs, HPAPI manufacturing, and complex chemistry problem-solving for the same multinational pharma and biotech customer base.
- PolyPeptide Group: Swiss-listed contract manufacturer specializing exclusively in peptide APIs. Direct competitor to Aspen API's peptide business with overlapping customers in GLP-1 and peptide therapeutics supply chains, and similar GMP peptide manufacturing capabilities.
- Cambrex: US-headquartered CDMO with strong small-molecule API development and manufacturing capabilities including HPAPIs and controlled substances. Direct competitor to Aspen API in the complex API CDMO segment, serving similar pharmaceutical customers across development and commercial stages.
- Siegfried Holding: Swiss API CDMO specializing in complex small-molecule APIs including controlled substances and steroids. Directly comparable to Aspen API's regulated API services, multi-site European manufacturing footprint, and focus on established commercial API products for originator and generic customers.
- Dishman Carbogen Amcis: Indian-headquartered CDMO specializing in HPAPIs, oncology APIs, and complex chemistry. Direct comparable to Aspen API's cytotoxic API capabilities at Cape Town and peptide/HPA chemistry strengths, serving similar pharmaceutical customers.
- Curia (formerly AMRI): Global CDMO offering API development and manufacturing services including small-molecule APIs and complex chemistry. Directly competes with Aspen API for development-stage CDMO contracts and serves overlapping pharmaceutical and biotech customers.
- Jubilant Pharmova (Jubilant Life Sciences): Indian integrated pharmaceutical company with CDMO services spanning small-molecule APIs and complex chemistry. Comparable to Aspen API's established API portfolio model and contract manufacturing scale, with similar global regulatory filing footprint.
Broad incumbents
- Catalent: Large US-headquartered CDMO with broad services spanning drug product, biologics, and APIs. While broader than Aspen API in scope, Catalent competes for similar development-stage and commercial API contracts and serves overlapping multinational pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Aspen social profiles
Digital presenceAspen compliance and trust
Trust signalCompliance9 records
Aspen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspen leadership team
Management profileNumber of profiles
Profiles7 records
Aspen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aspen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspen
What does Aspen do?
Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredient (API) development and manufacturing. The company provides end-to-end services from process development and analytical development through commercial manufacturing, supported by more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Operations span four manufacturing facilities in the Netherlands, South Africa, and the United States, with regulatory approvals from US FDA, EMA, PMDA, EDQM, and other major health authorities.
Is Aspen a public or private company?
Aspen is a private company. It is classified as corporate owned and is currently operating.
When was Aspen founded?
Aspen was founded in 1923. It employs 5,001 to 10,000 people.
Where is Aspen based?
Aspen is headquartered in Durban, South Africa, in the Africa region.
How does Aspen make money?
Two revenue lines are on record. Contract Development and Manufacturing (CDMO/CMO) is the primary driver. The others are established API Product Sales.
Who are Aspen's main competitors?
Direct peers on record are Axplora (formerly Novasep), Piramal Pharma Solutions, Lonza, PolyPeptide Group, Cambrex, Siegfried Holding, Dishman Carbogen Amcis, Curia (formerly AMRI) and Jubilant Pharmova (Jubilant Life Sciences). Catalent is listed as a broad incumbent.
Does Aspen have an API?
No public API is recorded for Aspen.
What industry is Aspen in?
Aspen's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its SIC code is 8731.